The role of hyperthermia as a treatment for non-muscle invasive bladder cancer

@article{Bahouth2016TheRO,
  title={The role of hyperthermia as a treatment for non-muscle invasive bladder cancer},
  author={Zaher Bahouth and Sarel Halachmi and Boaz Moskovitz and Ofer Nativ},
  journal={Expert Review of Anticancer Therapy},
  year={2016},
  volume={16},
  pages={189 - 198}
}
ABSTRACT Non-muscle invasive bladder cancer (NMIBC) has a high tendency for recurrence and progression. Currently, all known intravesical agents are associated with adverse effects (AEs) and limited efficacy. The combination of hyperthermia (HT) with intravesical Mitomycin C (MMC) chemotherapy has been shown to improve outcomes. The added efficacy of HT to MMC was first shown in preclinical studies. The reports on patients with NMIBC have indicated that the treatment is safe and well tolerated… 
A Pilot Study of Radiotherapy and Local Hyperthermia in Elderly Patients With Muscle-Invasive Bladder Cancers Unfit for Definitive Surgery or Chemoradiotherapy
TLDR
The outcomes from this pilot study indicate that thermoradiotherapy is a feasible therapeutic modality in elderly MIBC patients unfit for surgery or CTRT and HTRT is well-tolerated, allows bladder preservation and function, achieves long-term satisfactory locoregional control and is devoid of significant treatment-related morbidity.
Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms
TLDR
An overview of recent studies on the various macroscopic and microscopic biological effects of hyperthermia is provided, indicating the significance of these effects on current treatments and suggesting how they will help design novel future treatments.
Hyperthermic MMC—A Systematic Review
A systematic review relating to hyperthermic MMC in NMIBC was conducted. This was to identify the oncological outcomes from with hyperthermic mitomycin C for NMIBC. This chapter covers systematic
Thermo-chimiothérapie intravésicale par radiofréquence pour le traitement du cancer non invasif de la vessie
Le carcinome urothélial non invasif de la vessie (n’envahissant pas le détrusor) est grevé d’un risque de récidive significatif malgré les instillations endovésicales adjuvantes avec des agents

References

SHOWING 1-10 OF 52 REFERENCES
Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience.
Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients.
TLDR
The efficacy and safety results confirm those reported in previously published studies, suggesting the promising value of this combined treatment modality for both prophylactic and ablative patients.
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression
TLDR
ICLMH significantly increases the DFI of NMIBC patients with high EORTC score for recurrence and progression, and is associated significantly and independently with a higher risk of recurrence after ICLMH treatment.
Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
TLDR
Endovesical thermochemotherapy appears to be more effective than standard endovesical chemotherapy as an adjuvant treatment for superficial bladder tumors at 24-month follow-up, despite an increased but acceptable local toxicity.
Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party
TLDR
Treatment with intravesical hyperthermia and MMC appears a safe and effective treatment in patients with primary or BCG-failing CIS, which remains approximately 50% after 2 years.
Thermochemotherapy for Non-Muscle-Invasive Bladder Cancer: Is There a Chance to Avoid Early Cystectomy?
TLDR
Thermochemotherapy could be considered an additional tool in patients refractory to intravesical therapies before considering early cystectomy in high-risk bladder cancer nonresponders to previous therapy.
...
...